CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Moderna rallies past $100 billion valuation ahead of quarterly results

By Reuters News

** Shares of Moderna MRNA.O rise 10.2% to $251.67

** At current levels, Moderna's market capitalization topped the $100 bln mark, adding roughly $8 bln in market value from the previous close

** Last month, late-stage data showed vaccine intismeran, being jointly developed by Moderna and Merck MRK.N, plus Merck's Keytruda cut the risk of melanoma death or recurrence by 42% and the risk of the cancer's spread by 38%, compared with Keytruda alone

** Moderna is scheduled to report third-quarter results on Friday, with investors expected to focus on vaccine partnership payments, updates on the cancer vaccine

** Stock trades about 1% below its record intraday high of $254.48 touched last month

** Including session moves, MRNA up over eight-fold this year

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk